Blood biomarker may predict Alzheimer's progression differently in men

A blood test does not lie, exactly. It reports a number. The question raised by a new mini-review in Brain Medicine, which gathers and weighs a decade of scattered findings, is whether clinicians have been reading the same number in two different ways without realizing it. The marker is plasma neurofilament light chain, known as NfL, a fragment of the inner scaffolding that holds a neuron's long fibers open. When an axon frays, the fragment escapes into the blood. Pulling together evidence from teams across the field, the synthesis assembled by researchers at Fudan University and Wuhan University argues that the very same level of this protein may carry heavier weight in a man than in a woman.

Think of NfL as smoke from a slow fire. It does not name the cause, and it rises in many disorders, not only Alzheimer's. But once amyloid or tau pathology has framed the diagnosis, the review explains, this humble protein offers something the older tools struggle to provide: a minimally invasive, repeatable measure of how fast neurons are dying. Why does that matter so much? Because the alternatives are punishing. Positron emission tomography is costly and scarce. Spinal fluid analysis means a needle in the back, hard to repeat. A vial of blood, by contrast, can be drawn again and again, charting the trajectory of an illness the way a tide gauge charts the sea.

The strength of a review lies in pattern, not in any single result, and here the pattern is striking. Analysis of existing cohorts shows elevated plasma NfL not only in dementia but in the prodromal stage, and even in the preclinical phase before symptoms surface. And how early can the smoke be sensed? In families carrying autosomal dominant mutations, the review notes, levels begin climbing measurably years ahead of expected onset, in some studies up to fifteen years before the first lapse of memory. Higher concentrations align with poorer scores on standard cognitive screens, with shrinkage of the hippocampus on MRI, and with dimmed metabolism on FDG-PET. Within the field's AT(N) framework, NfL has become the "N," the indicator of neurodegeneration that rounds out the amyloid and tau picture.

What makes neurofilament light so valuable is its honesty about motion. It does not merely tell us that damage exists. It tells us how quickly it is unfolding, and that is precisely what clinicians and trials need."